This may make you feel dizzy or lightheaded or cause a headache
Background— In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), dual therapy did not reduce cardiovascular or renal outcomes compared with
The results of this trial demonstrate that in patients with hypertension and diabetic nephropathy, a telmisartan-based regimen is superior to a
Interpretation In people at high vascular risk, telmisartan’s eff ects on major renal outcomes are similar to ramipril
Conclusion: This study demonstrated that telmisartan effectively and safely reduces proteinuria in chronic kidney disease patients
Please
Telmisartan is not safe for use in pregnancy
Hypothesis
1–5
Detailed Telmisartan dosage information for adults
49 Excluding those dogs in which combination therapy was tested, 6 dogs (n = 4 enalapril-treated and n = 2 telmisartan treated) were removed from the present study prior to day 120 due to Δ Many drugs must have their doses adjusted to renal function in patients with CKD stage 3 or higher, i
The study revealed a positive trend – a decrease in the ratio of protein / creatinine in urine, which confirms the effectiveness of telmisartan in complex therapy
Your doctor may adjust your dose as needed
a composite of a doubling of serum creatinine concentration, end-stage renal disease (need for long-term Kidney problems, which may get worse if you already have kidney disease
Aims: This study assessed the clinical efficacy and safety of telmisartan, an angiotensin II receptor blocker with a long terminal elimination half-life and almost exclusively excreted in bile, in patients with varying severity of chronic kidney disease (CKD)
Animals